Oxidative stress and heart failure

Coronary Artery Disease

Volumn 14, Issue 2, 2003, Pages 109-113

  MacCarthy, Philip A ^a,b   Shah, Ajay M ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Heart failure; Oxidative stress; Reactive oxygen species; Superoxide

Indexed keywords

NITRIC OXIDE SYNTHASE; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; XANTHINE OXIDASE;

APOPTOSIS; EXTRACELLULAR MATRIX; HEART FAILURE; HEART MUSCLE CONTRACTILITY; HEART VENTRICLE HYPERTROPHY; HEART VENTRICLE REMODELING; HUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; REVIEW;

ANTIOXIDANTS; FREE RADICALS; GREAT BRITAIN; HEART FAILURE, CONGESTIVE; HUMANS; OXIDATIVE STRESS; REACTIVE OXYGEN SPECIES; SYNDROME; UNITED STATES;

EID: 0038070130     PISSN: 09546928     EISSN: None     Source Type: Journal    
DOI: 10.1097/00019501-200304000-00003     Document Type: Review

References (41)

1. Lenfant C. Report of the task force on research in heart failure. Circulation 1994; 90:1118-1123.
2. Sies H (editor): Oxidative stress: oxidants and antioxidants. New York: Academic Press; 1991.
3. Myers CE, McGuire WP, Liss RH, Ifrim I, Grotzinger K, Young RC. Adriamycin: the role of lipid peroxidation in cardiac toxicity and tumour response. Science 1977; 197:165-167.
4. Siveski-Iliskovic N, Hill M, Chow DA, Singal PK. Probucol protects against adriamycin cardiomyopathy without interfering with its antitumor effect. Circulation 1995; 91:10-15.
5. Singal PK, Kapur N, Dhillon KS, Beamish RE, Dhalla AK. Role of free radicals in catecholamine-induced cardiomyopathy. Can J Physiol Pharmacol 1982; 60:1390-1397.
6. Dhalla AK, Hill MF, Singal PK. Role of oxidative stress in transition of hypertrophy to heart failure. J Am Coll Cardiol 1996; 28:506-514. In a chronic pressure-overload model of left ventricular hypertrophy/heart failure in the guinea pig, increased cardiac oxidative stress was demonstrated at the heart failure stage. Vitamin E therapy significantly improved haemodynamic function in aortic-banded animals.
7. Prasad K, Karla J, Bharadwaj B. Increased chemiluminescence of polymorphonuclear leukocytes in dogs with volume overload heart failure. Br J Exp Path 1989; 70:463-468.
8. Hill MF, Singal PK. Antioxidant and oxidative stress changes during heart failure subsequent to myocardial infarction in rats. Am J Pathol 1996; 148:291-300.
9. Sobotka PA, Brottman MD, Weitz Z, Birnbaum AJ, Skosey JL, Zarling EJ. Elevated breath pentane in heart failure reduced by free radical scavenger. Free Radic Biol Med 1993; 14:643-647.
10. McMurray J, Chopra M, Abdullah I, Smith WE, Dargie HJ. Evidence of oxidative stress in chronic heart failure in humans. Eur Heart J 1993; 14:1493-1498.
11. 2α (a marker of oxidative stress) were measured in 51 patients undergoing cardiac surgery and found to be significantly elevated. These levels were also correlated with the degree of left ventricular (LV) dysfunction. This was the most convincing demonstration in the literature of increased oxidative stress in the failing human heart, using a more reliable marker than previous studies and correlating it with LV dysfunction.
12. Ellis GR, Anderson RA, Lang D, Blackman DJ, Morris RHK, Morris-Thurgood J, et al. Neutrophil superoxide anion-generating capacity, endothelial function and oxidative stress in chronic heart failure: effects of short and long-term vitamin C therapy. J Am Coll Cardiol 2000; 36:1474-1482.
13. Ide T, Tsutsui H, Kinugawa S, Suematsu N, Hayshidani S, Ichikawa K, et al. Direct evidence for increased hydroxyl radicals originating from superoxide in the failing myocardium. Circ Res 2000; 86:152-157. Using electron spin resonance spectroscopy in a rapid pacing canine model of heart failure, this was the first direct demonstration of an increase in reactive oxygen species (ROS) production by the failing myocardium. A previous study by the same group identified the mitochondria as being an important source of ROS within the myocyte.
14. Gupta M, Singal PK. Higher antioxidative capacity during a chronic stable heart hypertrophy. Circ Res 1989; 64:398-406.
15. Lebovitz RM, Zhang H, Vogel H, Cartwright J Jr, Dionne L, Lu N, et al. Neurodegeneration, myocardial injury and perinatal death in mitochondrial superoxide dismutase-deficient mice. Proc Natl Acad Sci USA 1996; 93:9782-9787.
16. Dieterich S, Bieligk U, Beulich K, Hasenfuss G, Prestle J. Gene expression of antioxidant enzymes in the human heart. Circulation 2000; 101:33-39.
17. Baumer AT, Flesch M, Wang X, Shen Q, Feuerstein GZ, Bohm M. Antioxidative enzymes in human hearts with idiopathic dilated cardiomyopathy. J Mol Cell Cardiol 2000; 32:121-130.
18. Kunsch C, Medford RM. Oxidative stress as a regulator of gene expression in the vasculature. Circ Res 1999; 85:753-766.
19. Harrison DG. Cellular and molecular mechanisms of endothelial cell dysfunction. J Clin Invest 1997; 100:2153-2157.
20. Nielsen VG, Tan S, Baird MS, Samuelson PN, McCammon AT, Parks DA. Xanthine oxidase mediates myocardial injury after hepato-enteric ischaemia-reperfusion. Crit Care Med 1997; 25:1044-1050.
21. Ekelund UEG, Harrison RW, Shokek O,Thakkar RN, Tunin RS, Senzaki H, et al. Intravenous allopurinol decreases myocardial oxygen consumption and increases mechanical efficiency in dogs with pacing-induced heart failure. Circ Res 1999; 85:437-445. This study showed a four-fold increase in xanthine oxidase activity in failing myocardium. It also demonstrated an interesting effect of the xanthine oxidase inhibitor, allopurinol, which increased contractility in the failing hearts whilst simultaneously decreasing myocardial oxygen consumption. This effect on myocardial efficiency has not been seen with any other inotropic agent.
22. Griendling KK, Sorescu D, Ushio-Fukai M. NAD(P)H oxidase; role in cardiovascular biology and disease. Circ Res 2000; 86:494-501.
23. Pagano PJ, Clark JK, Cifuentes-Pagano ME, Clark SM, Callis GM, Quinn MT. Localization of a constitutively active phagocyte-like, NADPH oxidase in rabbit aortic adventitia: enhancement by angiotensin II. Proc Natl Acad Sci USA 1997; 94:14483-14488.
24. Bayraktutan U, Blayney L, Shah AM. Molecular characterization and localization of the NAD(P)H oxidase components gp91-phox and p22-phox in endothelial cells. Arterioscl Thromb Vasc Biol 2000; 20:1903-1911.
25. Cosentino F, Katusic ZS. Tetrahydrobiopterin and dysfunction of endothelial nitric oxide synthase in coronary arteries. Circulation 1995; 91:139-144.
26. Meldrum DR. Tumour necrosis factor in the heart. Am J Physiol 1998; 274:R577-R595. A comprehensive review of all aspects of the cardiac effects of tumour necrosis factor-α.
27. Cheng W, Li B, Kajstura J, Li P, Wolin MS, Sonnenblick EH, et al. Stretch-induced programmed myocyte cell death. J Clin Invest 1995; 96:2247-2259.
28. Xu KY, Zweier JL, Becker LC. Hydroxyl radical inhibits sarcoplasmic reticulum Ca(2+)-ATPase function by direct attack on the ATP binding site. Circ Res 1997; 80:76-81.
29. Xie YW, Kaminski PM, Wolin MS. Inhibition of rat cardiac muscle contraction and mitochondrial respiration by endogenous peroxynitrite formation during posthypoxic reoxygenation. Circ Res 1998; 82:891-897.
30. Irani K. Oxidant signaling in vascular cell growth, death, and survival: a review of the roles of reactive oxygen species in smooth muscle and endothelial cell mitogenic and apoptotic signaling. Circ Res 2000; 87:179-183.
31. Nakamura K, Fushimi K, Kouchi H, Mihara K, Miyazaki M, Ohe T, et al. Inhibitory effects of antioxidants on neonatal rat cardiac myocyte hypertrophy induced by tumor necrosis factor-α and angiotensin II. Circulation 1998; 98:794-799.
32. Kinugawa S, Tsutsui H, Hayashidani S, Ide T, Suematsu N, Satoh S, et al. Treatment with dimethylthiourea prevents left ventricular remodeling and failure after experimental myocardial infarction in mice: role of oxidative stress. Circ Res 2000; 87:392-398.
33. Kiowski W, Sütsch G, Schalcher C, Brunner HP, Oechslin E. Endothelial control of vascular tone in chronic heart failure. J Cardiovasc Pharmacol 1998; 32 (suppl 3):S67-S73.
34. Hornig B, Arakawa N, Kohler C, Drexler H. Vitamin C improves endothelial function of conduit arteries in patients with chronic heart failure. Circulation 1998; 97:363-368. In 15 patients with New York Heart Association class III heart failure, the effects of intrabrachial infusion of vitamin C were assessed and shown to improve flow-dependent vasodilatation. Four weeks of oral vitamin C therapy also improved endothelial function in these patients.
35. MacCarthy PA, Shah AM. Impaired endothelium-dependent regulation of ventricular relaxation in pressure-overload cardiac hypertrophy. Circulation 2000; 101:1854-1860.
36. Yusuf S, Dagenais G, Pogue J, Bosch J, Sleight P. Vitamin E supplementation and cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000; 342:154-160.
37. Ghatak A, Brar MJ, Agarwal A, Goel N, Rastogi AK, Vaish AK, et al. Oxy free radical system in heart failure and therapeutic role of oral vitamin E. Int J Cardiol 1996; 57:119-127.
38. Keith ME, Jeejeebhoy KN, Langer A, Kurian R, Barr A, O'Kelly B, et al. A controlled clinical trial of vitamin E supplementation in patients with congestive heart failure. Am J Clin Nutr 2001; 73:219-224.
39. Morisco C, Trimarco B, Condorelli M. Effect of coenzyme Q10 therapy in patients with congestive heart failure: a long-term multicentre randomised study. Clin Invest 1993; 71:S134-S136.
40. Givertz MM, Colucci WS. New targets for heart failure therapy: endothelin, inflammatory cytokines and oxidative stress. Lancet 1998; 352 (suppl 1):34-38.
41. Kukin ML, Kalman J, Charney RH, Levy DK, Buchholz-Varley C, Ocampo ON, et al. Prospective, randomised comparison of effect of long-term treatment with metoprolol or carvedilol on symptoms, exercise, ejection fraction and oxidative stress in heart failure. Circulation 1999; 99:2645-2651.